Delving into the Latest Updates on Staphylococcus aureus vaccine conjugate pentavalent (GlaxoSmithKline) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Conjugated vaccine

Synonyms

PentaStaph, StaphVAXPentavalent

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious Diseases

Active Indication-

Inactive Indication

Staphylococcal Infections

Originator Organization

Nabi Biopharmaceuticals

Active Organization-

Inactive Organization

Aviragen Therapeutics, Inc.

GSK Plc

Drug Highest PhaseDiscontinuedPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

S. aureus is the most common pathogen involved in prosthetic joint infection. StaphVAX® is a vaccine to prevent these infections, which conjugates the purified capsular polysaccharides of S. aureus to a carrier protein. It is currently being evaluated for future licensing. This study aims to demonstrate the safety and immunogenicity of a single dose of StaphVAX in patients who are candidates for knee or hip arthroplasty.

Start Date01 Dec 2004

Sponsor / Collaborator

Nabi Biopharmaceuticals

100 Clinical Results associated with Staphylococcus aureus vaccine conjugate pentavalent (GlaxoSmithKline)

Login to view more data

100 Translational Medicine associated with Staphylococcus aureus vaccine conjugate pentavalent (GlaxoSmithKline)

Login to view more data

100 Patents (Medical) associated with Staphylococcus aureus vaccine conjugate pentavalent (GlaxoSmithKline)

Login to view more data

1

Literatures (Medical) associated with Staphylococcus aureus vaccine conjugate pentavalent (GlaxoSmithKline)

01 Dec 2009·IDrugs : the investigational drugs journal

World Vaccine Congress Lyon - Terrapinn's 11th Annual Congress.

Article

Author: Sovran, Liza

The 11th Annual World Vaccine Congress, held in Lyon, included topics covering new therapeutic developments in the field of vaccines. This conference report highlights selected presentations on the role of big pharma in vaccine development, the future direction of vaccine R&D, influenza preparedness in Europe, and vaccines for Staphylococcus aureus, CMV and cancer. Investigational drugs discussed include an H5N1 influenza vaccine program from Baxter International Inc/DynPort Vaccine Co LLC, FP-01 (Immune Targeting Systems Ltd), FluGEM (Mucosis BV), a nonstructural protein-1-altered live-attenuated influenza vaccine candidate from Vivaldi Biosciences Inc, PentaStaph (GlaxoSmithKline plc) and StaphVAX (Nabi Biopharmaceuticals), VCL-CB01 (Vical Inc) and astuprotimut-r (GlaxoSmithKline).

100 Deals associated with Staphylococcus aureus vaccine conjugate pentavalent (GlaxoSmithKline)

Login to view more data